Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma — CAPITAL

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Clinical Trial

Official title:
A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)

Status Active, not recruiting

Clinical Trial Summary

This study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).

Clinical Trial Description

The study protocol follows a modular design. The study will investigate the safety and efficacy of capivasertib monotherapy in participants with R/R Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL). ;

Study Design

Related Conditions & MeSH terms

Lymphoma
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Clinical Trial Details

NCT number	NCT05008055
Study type	Interventional
Source	AstraZeneca
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	November 3, 2021
Completion date	June 28, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05105867` - CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies	Early Phase 1
Recruiting	`NCT02134262` - Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes	Phase 1/Phase 2
Recruiting	`NCT06189391` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201	Phase 1
Enrolling by invitation	`NCT05797948` - GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	N/A